scispace - formally typeset
S

Silvia C. Formenti

Researcher at Cornell University

Publications -  396
Citations -  32827

Silvia C. Formenti is an academic researcher from Cornell University. The author has contributed to research in topics: Radiation therapy & Breast cancer. The author has an hindex of 74, co-authored 372 publications receiving 25850 citations. Previous affiliations of Silvia C. Formenti include Catholic University of the Sacred Heart & New York University.

Papers
More filters
Journal ArticleDOI

Human monoclonal antibodies reactive with colon carcinoma: identification by a novel screening procedure with xenografts.

June Kan-Mitchell, +2 more
- 01 Jan 1989 - 
TL;DR: Human regional lymph nodes contain a high proportion of B lymphocytes sensitized to the autochthonous tumor, and immunostaining of human colon tumor xenografts can readily identify human MAbs reactive with colon carcinomas.
Journal ArticleDOI

Impact of the COVID-19 breast cancer screening hiatus on clinical stage and racial disparities in New York City

Genevieve A. Fasano, +20 more
- 01 May 2022 - 
TL;DR: The impact of the COVID-19 mammography screening hiatus as well as of post-hiatus efforts promoting restoration of elective healthcare on breast cancer detection patterns and stage distribution is unknown as discussed by the authors .
Journal Article

In regard to kao et al.: concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer : results from two consecutive phase I/II trials

Silvia C. Formenti
- 01 Jan 2005 - 
Journal ArticleDOI

Adenosine Regulates Radiation Therapy–Induced Anti-Tumor Immunity

Erik Wennerberg, +2 more
- 01 Oct 2016 - 
TL;DR: It is shown that adenosine regulates the ability of RT to induce anti-tumor immunity, affecting both DC maturation and T cell activation and suggesting that CD73-blockade is a promising strategy to improve synergy of RT and immunotherapy.
Journal ArticleDOI

Phase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancer.

Jasmeet Chadha Singh, +14 more
- 20 Sep 2011 - 
TL;DR: It is proposed that combination RAD001 and carboplatin may have activity in triple-negative breast cancer and clinical benefit and toxicity of this combination in women who had received 0-3 prior chemotherapy regimens for metastatic disease are determined.